StockWatch
·

INSECTICIDES (INDIA) LTD. Q2 FY27 Results

INSECTICIDQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue686.3112.2%7.6%
Total Income685.4711.1%7.1%
Expenditure610.349.3%8.7%
PBT75.1328.3%4.3%
Net Profit56.1728.0%5.0%
OPM13.47%2.41pp0.56pp
NPM8.19%1.08pp1.04pp
EPS19.3028.0%5.0%
View full financials

Chemicals sector read on adjusted PAT growth and margin trend shows revenue up 7.6% YoY but PAT down ~5% on margin compression (OPM 14.0%→13.5%, NPM 9.2%→8.2%), a below-par quarter despite topline growth.

INSECTICIDES (INDIA) · Q2 FY27 · THE VERDICT

Volume Down, Margins Pinched—But the Pipeline Holds

Revenue beat expectations despite a 6–7% volume decline, but profit fell 5% YoY as margins compressed. The quarter tests whether premium-mix gains are sustainable or a temporary offset.

12 Nov 2026 · 6 min read
Revenue

₹686.3 Cr

+7.6% YoY, +12.2% QoQ

PAT

₹56.2 Cr

-5% YoY, +28% QoQ

Gross margin

33.7%

-80 bps YoY

Volume trend

-6 to -7%

Offset by premium mix

Insecticides (India) reported a Q2 that looked better on the surface than underneath. Revenue of ₹686.3 crore met the premium-product narrative—up 7.6% despite a 6–7% volume drop—but the profit line told a different story. Net profit slid 5% to ₹56.2 crore, and gross margins compressed 80 basis points to 33.7%. This was not a quarter where premiumization delivered margin expansion; it was a quarter where premiumization prevented a sharper profit decline.

The quarter in three numbers

Start with volume. Management disclosed a 6–7% volume decline in Q2, driven by weak farmer sentiment post-monsoon disruption (El Niño impact). In prior commentary, management had guided for stabilization; instead, the trend deteriorated. To compensate, the company shifted its sales mix toward premium and specialty products—Maharatna, Focused Maharatna, and the nascent Kaeros brand—achieving ~4–5% value growth. That mix shift was real: premium products now represent 60%+ of the sales portfolio, with a 70% target over 2–3 years.

But premium mix alone does not offset 6–7% volume at current gross-margin structures. Gross margin fell to 33.7% from 34.5% a year ago, even as the company emphasized cost discipline and premiumization. EBITDA margin held at 13.5% (₹92.4 crore), but PAT declined to ₹56.2 crore from ₹59.2 crore, a 5% year-over-year drop. The profitability compression is real and unambiguous.

Claims graded against the numbers

What management said vs. what holds up

8% revenue growth in Q2

7.6% YoY growth; ₹686.3 Cr vs ₹637 Cr prior year

Supported (close call)

Premiumization and value growth offsetting volume decline

True on revenue (+7.6%); false on profit (PAT -5%) and margins (-80 bps)

Overstated on profitability impact

Working capital improving via operational focus

WC days 158 vs 151 (+7 days); inventory ₹814 Cr vs ₹744 Cr (+₹70 Cr)

Contradicted; deteriorated ₹34 Cr net

Margins consistent, profitability intact

Gross margin -80 bps, EBITDA flat, PAT -5%

Overstated; near-term compression evident

What changed on this call

Management raised or firmed three material pieces of guidance. Kaeros, the company's premium agrochemical brand, is scaling faster than initial targets. Originally guided at 50–60% CAGR, the company now explicitly targets ₹125–200 crore brand turnover by fiscal-year-end or FY28, with a longer-term path to double that. The brand has already hit ₹114 crore in H1 sales, a 50%+ CAGR pace. International business received its first quantified target: 40–50% CAGR growth toward ₹500 crore over 5 years, starting from a ~5% base. This is new specificity and a material shift in strategy away from domestic generics. Premium product mix target was raised to 70% over 2–3 years, from the current 60%+.

Conversely, capex timelines slipped. Dahej DCS plant, expected in H1, is now targeted for Q3 completion (by December 2026). Sotanala formulation unit is now targeted for April Q4, with technical manufacturing to follow in FY28. And volume remained unresolved—management conceded flat to slightly negative FY27 full-year volume instead of the stabilization previously implied. These are modest reversals, but they reveal execution pressure and an inability to arrest the volume decline near-term.

Bull-bear ledger
  • Kaeros 50%+ CAGR on track; ₹114 Cr H1 run-rate; 800k+ distributor network proven

  • Premium product mix now 60%+; 70% target over 2–3 years; demand-driven

  • International strategy newly quantified (₹500 Cr over 5Y, 40–50% CAGR); 15+ AIs filed

  • Capex (Dahej, Sotanala) positions for CDMO and cost efficiency recovery

  • Volume declined 6–7% in Q2; management concedes flat/negative FY27 full year

  • Gross margin down 80 bps despite premiumization narrative; PAT down 5% despite revenue +7.6%

  • Working capital deteriorated ₹34 Cr; inventory up ₹70 Cr; days up 7 despite 'strategic holding' claim

  • Capex slipped (Dahej Q3 vs H1, Sotanala Q4 vs H2); execution risk evident

Risks, ranked by how much they should concern a holder

Margin compression sustained

Medium

Gross margin down 80 bps despite premiumization. If volume decline persists and mix shift slows, margin could compress further. Industry consolidation and pricing pressure from larger players limit near-term recovery.

Volume stabilization delayed into FY28

Medium

6–7% decline in Q2; management now concedes flat/negative FY27. If farmer sentiment remains weak or monsoon impact extends, stabilization could slip further. Near-term growth headwind.

Working capital deterioration continues

Medium

WC days up 7 to 158, inventory up ₹70 Cr, net WC up ₹34 Cr. If trend persists, cash generation is stressed, constraining capex or dividends. Seasonal normalization expected post-Diwali, but trend bears watching.

Capex execution delays cascade

Medium

Dahej slipped from H1 to Q3; Sotanala from H2 to Q4. Further delays could defer capex normalization and CDMO revenue ramp. Interest capitalization and working capital cycles prolonged.

International business early-stage execution risk

Medium

₹500 Cr over 5Y target is ambitious from a ~5% base. Registrations, CDMO deals, partner relationships nascent. Long cycle (1–2Y per registration). Regulatory complexity and China competition pose risks.

Macro volatility (monsoon, commodity prices)

Low-Medium

Q2 hit by El Niño; farmer profitability stressed. Crude/sea freight volatility passes through. Input cost inflation could compress margins further if pricing power is limited.

The street's view

Institutional ownership is flat and defensive. FII holdings slid marginally to 4.40% from 4.50% a quarter ago (−10 basis points), and DII holdings are essentially unchanged at 9.26%. Promoter ownership remains stable at 72.30%. No evidence of bulk buying or insider accumulation near current levels. The ownership profile suggests the market is neither excited nor panicked—a 'show me' stance. This matches the fundamental picture: management has a credible long-term pipeline, but near-term earnings are soft, and visibility on margin recovery is limited. Institutions are waiting for evidence that the premium-mix thesis translates to bottom-line strength before stepping in.

What to watch next
  • 1 · Q3 volume and margin trajectory

    Does volume stabilize into H2 as management projects, or does the 6–7% decline persist? If volume remains negative and mix shift slows, gross margin could compress further. Watch for management commentary on farmer sentiment and pre-Diwali sales trends in next earnings call.

  • 2 · Dahej and Sotanala capex completion

    Both plants are on the critical path for cost normalization and CDMO revenue ramp. Q3 update on Dahej progress (currently expected December 2026) and Q4 formulation unit startup (April 2027) are key execution milestones. Delays extend the margin recovery timeline.

  • 3 · Working capital normalization

    Current WC days of 158 are elevated. Management cited 'strategic inventory holding' pre-Diwali; normalization back toward 150–151 days post-festival would be a positive signal on cash generation and operational discipline. H2 working capital update will be scrutinized.

  • 4 · Kaeros margin structure clarity

    Kaeros H1 sales of ₹114 Cr are strong, but the gross-margin contribution (vs. core business) is not yet clear. As Kaeros scales toward ₹200 Cr, understanding its margin profile will be essential to assess whether premiumization thesis holds at consolidated level.

Insecticides (India) is executing on a credible long-term transformation: Kaeros is on a 50%+ CAGR path, international exposure is being built systematically, and a 30+ molecule pipeline is advancing. But the near-term quarter reveals a softer baseline than management's prior commentary implied. Volume is down, margins are compressing, working capital is deteriorating, and capex is slipping. The central question is whether premium mix and Kaeros scale can stabilize profitability before the broader cyclical headwind (farmer weakness, commodity volatility, weather disruption) extends further.

Q2 was not a disaster—the premium mix prevented it from being one. But it was not a vindication of the premiumization thesis either. Management is holding the line on long-term guidance (Kaeros ₹200 Cr, international ₹500 Cr), and the analyst community is watching execution closely. A steady operational quarter is in order to rebuild credibility on margins.

The single number to track from here: Gross margin. If Q3 stabilizes or expands from 33.7%, the premium-mix thesis regains credibility. If it compresses further, the structural headwinds (volume, commodity, competition) are winning, and near-term fair value is lower.

Informational and educational content only. Not investment advice.